Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)

Trial Profile

Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Therapeutic Use
  • Acronyms EYLEA-STRIE
  • Most Recent Events

    • 24 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top